


# Michigan *Candida auris* Surveillance Updates

Feb. 28, 2023




In efforts to keep our health care partners in Michigan updated on the emergence of *Candida auris*, the Michigan Department of Health and Human Services, Surveillance for Healthcare-Associated and Resistant Pathogens Unit will update the following data weekly.


**Fig 1. *Candida auris* Cases in Michigan by Case Type<sup>a</sup>, May 1, 2022 – February 28, 2023**




**Fig 2. Local Health Jurisdiction of Health Care Facility at *C. auris* Case Detection<sup>b</sup>**



**Fig. 3. *C. auris* Cases by Health Care Facility Type<sup>c</sup> at Detection<sup>b</sup>**



**Fig 4. Clinical *C. auris* Cases by Specimen Source**



**Fig 5. Clinical Isolate Antifungal Susceptibility Testing<sup>d</sup>, n = 54**

Antifungal Drug	MIC <sub>50</sub> (Range)	% Resistant
Amphotericin B	1 (0.5-1)	0
Anidulafungin	1 (0.06-4)	6 <sup>e</sup>
Capsogfungin	0.25 (0.06-2)	7 <sup>e</sup>
Micafungin	0.25 (0.06-2)	0
Fluconazole	128 (4 ->256)	98
Itraconazole	1 (0.12-2)	NA
Isavuconazole	1 (0.03-2)	NA
Posaconazole	0.5 (0.03-1)	NA
Voriconazole	1 (0.03-8)	NA

<sup>a</sup> **Case Type:** Clinical Case – *C. auris* identified in a specimen collected during the course of clinical care for the purpose of diagnosis or treatment of disease, such as from a blood, urine, respiratory, wound; Screening Case – *C. auris* identified in a sample collected to detect colonization, such as the axilla and/or groin; Screening-to-Clinical Case – an individual with *C. auris* initially detected from a screening test who subsequently had a clinical culture positive for *C. auris*.

<sup>b</sup> **Location at Detection** – Health care facility where the individual was present at the time the *C. auris* positive specimen was collected, which may or may not reflect the location where *C. auris* was acquired.

<sup>c</sup> **Health Care Facility Type:** LTACH – long-term acute care hospital; ACH – acute care hospital; vSNF – ventilator-capable skilled nursing facility; IRF – inpatient rehabilitation facility; SNF – skilled nursing facility; OP – outpatient setting

<sup>d</sup> **Antifungal Susceptibility Testing:** Performed by the CDC Antimicrobial Resistance Laboratory Network. There are currently no established *C. auris*-specific susceptibility breakpoints. Therefore, breakpoints are defined based on those established for closely related *Candida* species and on expert opinion. <https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html>

<sup>e</sup> **Echinocandin Resistance:** *C. auris* isolates demonstrating echinocandin resistance represent four isolates from epi-linked cases from one outbreak. An echinocandin drug continues to be the recommended initial therapy for treatment of *C. auris* infections. <https://www.cdc.gov/fungal/candida-auris/c-auris-treatment.html>